We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock
SRRA

Delisted

SRRA was delisted on the 30th of June, 2022.

Back to rankings

51 hedge funds and large institutions have $115M invested in Sierra Oncology, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more capital invested

Capital invested by funds: $45M → $115M (+$70.4M)

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

24% more funds holding

Funds holding: 41 → 51 (+10)

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
51
Holders Change
+10
Holders Change %
+24.39%
% of All Funds
1.16%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
19
Increased
9
Reduced
8
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$3.23M
2
6CM
683 Capital Management
New York
+$2.21M
3
CS
Candriam SCA
Luxembourg
+$1.44M
4
SFM
Sphera Funds Management
Israel
+$1.32M
5
Renaissance Technologies
Renaissance Technologies
New York
+$996K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3M
2
DM
Deerfield Management
New York
-$2.5M
3
O
OrbiMed
New York
-$1.2M
4
SM
Sabby Management
Florida
-$827K
5
PAM
Panagora Asset Management
Massachusetts
-$308K
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
1
Frazier Management
Washington
$30.3M – – –
PA
2
Perceptive Advisors
New York
$18.6M +$3.23M +33,620 +37%
O
3
OrbiMed
New York
$11.9M -$1.2M -12,500 -13%
NLVP
4
New Leaf Venture Partners
New York
$10.4M – – –
VC
5
Vivo Capital
California
$9.1M – – –
DM
6
Deerfield Management
New York
$6.57M -$2.5M -25,973 -37%
Millennium Management
7
Millennium Management
New York
$4.56M +$648K +6,746 +28%
6CM
8
683 Capital Management
New York
$3.44M +$2.21M +23,044 New
IHM
9
Iguana Healthcare Management
New York
$2.98M +$481K +5,000 +33%
Renaissance Technologies
10
Renaissance Technologies
New York
$2.75M +$996K +10,358 +128%
AC
11
AWH Capital
Texas
$2.56M +$1.65M +17,125 New
CS
12
Candriam SCA
Luxembourg
$2.24M +$1.44M +15,000 New
SFM
13
Sphera Funds Management
Israel
$2.05M +$1.32M +13,750 New
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$1.03M +$665K +6,923 New
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$933K -$3M -31,250 -83%
GT
16
Greenleaf Trust
Michigan
$776K -$8.94K -93 -2%
SAM
17
Sectoral Asset Management
Quebec, Canada
$752K – – –
Fidelity Investments
18
Fidelity Investments
Massachusetts
$637K – – –
BCM
19
Bridgeway Capital Management
Texas
$613K – – –
Two Sigma Investments
20
Two Sigma Investments
New York
$489K +$315K +3,277 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$280K +$180K +1,875 New
EP
22
Eversept Partners
New York
$250K +$161K +1,675 New
JG
23
Jefferies Group
New York
$224K +$144K +1,500 New
William Blair & Company
24
William Blair & Company
Illinois
$171K – – –
PAM
25
Panagora Asset Management
Massachusetts
$163K -$308K -3,209 -75%
1
2 3

SRRA Hedge Fund Activity: Q4 2017 in Review

51 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q4 2017, worth a combined $115M — up 156% from $45M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new SRRA positions and 9 closed out — a net gain of 10 holders — while 9 added to existing stakes and 8 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $3.23M. The largest seller was Point72 Asset Management, cutting an estimated $3M.

  • 51 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q4 2017, up from 41 in Q3 2017.
  • Funds reported $115M of Sierra Oncology, Inc. Common Stock stock for Q4 2017, up 156% quarter-over-quarter.
  • 19 funds opened new Sierra Oncology, Inc. Common Stock positions in Q4 2017 and 9 closed out, a net change of +10 holders.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q4 2017 was Perceptive Advisors, an estimated $3.23M added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q4 2017 was Point72 Asset Management, an estimated $3M sold.

Based on aggregated 13F filings for Q4 2017.